1224 ET - Bluebird bio's deal to be taken private will leave investors with a rich reward or a steep haircut, depending on sales of the company's gene therapies over the next three years. Analysts at William Blair think it will be the latter. Bluebird holders will get an initial $3 a share, 57% below Thursday's closing price, but contingent value rights that would be triggered by 12-month sales of $600 million would bring another $6.84 a share, for a 40% premium. William Blair says it currently models bluebird's sales reaching only $546.4 million in 2027, making the probability of achieving the CVR contingency low. Bluebird slide 39% to $4.29. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
February 21, 2025 12:24 ET (17:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.